1
FDA Signals Movement on Peptides, But Not Full Approval
The U.S. Food and Drug Administration has scheduled a July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting to review several peptide-related substances for possible inclusion on the 503A bulks list. Substances under discussion include BPC-157, KPV, MOTS-C, Semax, and others.
Here is the reality. This is not FDA approval of peptides as drugs. It is a regulatory review that could allow certain peptides to be used in compounding under specific conditions.
Why this matters The peptide and GLP-1 market is no longer just a prescribing trend. It is becoming a research, compliance, and biomarker opportunity. Sponsors will need access to de-identified samples tied to metabolic health, drug exposure, longitudinal outcomes, adverse events, and responder versus non-responder profiles.
Endo is positioned as a biospecimen and data access partner for GLP-1 and peptide-related research, especially where sponsors need real-world clinical specimens, remnant blood, plasma, serum, and associated de-identified patient data. If you are interested in partnering to support these innitiatives, please contact: David Curley @ [email protected]
2
FDA Moves Toward Real-Time Clinical Trials
FDA announced major steps toward implementing real-time clinical trials, including proof-of-concept trials designed to report endpoints and data signals to FDA in real time. FDA also released a request for information for a proposed real-time clinical trial pilot program expected later in 2026.
This is important because traditional clinical trials can be slow, expensive, and operationally heavy. Real-time trial infrastructure could improve safety monitoring, speed up decision-making, and reduce delays between data collection and regulatory review.
Why this matters: Real-time trials will require faster sample access, cleaner metadata, better chain-of-custody discipline, and reliable de-identification workflows.
Labs that can support real-time research workflows will become more attractive to sponsors. Endo can help independent labs organize your remnant sample programs so they are not just collecting specimens, but creating research-ready assets. Contact: David Curley @ [email protected]
3
AI and Automation Are Becoming Core Lab Growth Drivers
Labcorp reported strong first-quarter 2026 results, with leadership pointing to AI, automation, and a “technology-first” operating model as major growth drivers. The company also raised full-year guidance and highlighted momentum across diagnostics and lab services.
Labcorp’s broader automation strategy includes work with Roche to bring fully automated mass spectrometry into U.S. clinical labs, which reflects a larger industry trend toward higher throughput, lower manual burden, and more scalable complex testing.
Why this matters: The bar is rising for every lab. Sponsors and research partners will increasingly expect cleaner data, fewer manual errors, stronger inventory controls, and faster specimen workflows.
Endo can help smaller and mid-sized independent labs bridge the gap between routine testing operations and high-value testing operations. In other words: the big labs are automating, but independent labs still have valuable specimens. We can help streamline operations with custom panels built with reimbursement in mind and implement revenue opportuntiies like remnant sample programs. Contact: Jason Heffner @ [email protected]
4
Rapid NGS and Precision Medicine Continue Moving Closer to the Front Line
Clinical diagnostics continues to move toward faster genomic testing, earlier molecular profiling, and front-line precision medicine. Industry education and clinical lab programming in 2026 continue to emphasize rapid NGS, infectious disease sequencing, oncology profiling, automation, and AI-supported interpretation.
This trend matters because many clinical decisions are no longer based only on broad disease categories. Increasingly, they depend on molecular signatures, biomarker status, treatment response, and deeper clinical context.
Why this matters: NGS and precision medicine research depend heavily on specimen quality and annotation density. A sample by itself has value. A sample with diagnosis, treatment history, medication exposure, test result history, and outcomes has much greater value.
Endo helps you create research-ready biospecimen channels with clinical relevance. If you want to learn how to turn your waste into a profitable part of your business contact: David Curley @ [email protected],
5
LDT Oversight Remains Unsettled, but Quality Expectations Are Not Going Away
The FDA’s 2024 laboratory-developed test rule was vacated by a federal court in 2025, and FDA subsequently moved to roll back the rule. Reuters reported that FDA would formally rescind the increased oversight rule following the court decision.
Even with the FDA rule rolled back, the broader issue remains alive. Labs developing specialized tests will still face scrutiny from payers, researchers, health systems, and commercial partners around analytical validity, clinical validity, documentation, quality systems, and data governance.
Why this matters: The market may have avoided one regulatory hammer, but it did not avoid accountability. Research partners will still prefer labs that can demonstrate strong compliance, clean documentation, and reliable handling of de-identified data and biospecimens.
Our strongest lab partners are the ones that operate with discipline: proper consent language where needed, clean manifests, strong sample tracking, and clear separation of PHI from de-identified research data. We can help make this simple for you: Contact: Jason Heffner @ [email protected]
Industry Events to Watch
ASM Microbe 2026
June 4 to 7, 2026 Washington, D.C.
ASM Microbe is one of the largest microbiology and infectious disease meetings, covering microbial science, infectious disease diagnostics, antimicrobial resistance, sequencing, and laboratory innovation.
BIO International Convention 2026
June 22 to 25, 2026 San Diego, California
BIO remains one of the largest global biotechnology partnering events, bringing together pharma, biotech, diagnostics, research services, investors, and commercialization partners.
ADLM 2026 Annual Scientific Meeting & Clinical Lab Expo
July 26 to 30, 2026 Anaheim, California
ADLM 2026 will bring together leaders in laboratory medicine, diagnostics, molecular testing, mass spectrometry, clinical chemistry, and lab operations. ADLM notes that early registration savings are available through June 4, and the meeting takes place July 26 to 30 in Anaheim.
If you are attending any of these events, let’s coordinate time to connect. Contact David Curley @ [email protected]
Attending ADLM in July?
ADLM (formerly AACC) - July 26-30, Anaheim, CA. - ENDO will be hosting a networking Happy Hour at a nearby location (details will be released next month). Our networking events are ususally a big hit with the opportunity to meet other lab pros from around the Country, and potentially get some new ideas on what may be working for others.
We are all attempting to improve our businesses and we can learn from each other. We make networking easy while enjoying some cocktails and food.
Good food, good cocktails, good people, good ideas = business improvement opportunities
Please contact us if you plan to attend and we will reserve a spot for you.
email: [email protected] or [email protected]
Send us an email letting us know! [ [email protected], [email protected]]
Final Takeaway
The clinical laboratory market is moving in a clear direction:
More automation. More data. More precision medicine. More regulatory scrutiny. More demand for high-quality specimens.
That creates a major opportunity for our partner labs.
Independent laboratories are sitting on valuable remnant specimens every day. Most are not monetizing them properly. We can help convert those underutilized samples into compliant, research-ready assets that support drug development, diagnostics, biomarker discovery, and real-world evidence.
The punchline: samples are no longer waste. With the right data and compliance structure, they are strategic assets. We can help turn your waste into a profit generating program.
